ARTV — Artiva Biotherapeutics, Inc. Common Stock

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates ARTV Bullish with a Setup Score of 37, net conviction 38, actionability 36. How the Setup Score works →

Total Setup Score37
Directional BiasBullish
Net Conviction38
Actionability36 (in range)

Key signals behind this score

About Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$6.94
Market Cap$332M
Float19.4M
Shares Outstanding48.9M
Price/Sales (TTM)8.11
vs. Analyst Target+415.9% to analyst PT
Dividend RateNone
Analyst Target Price$35.80

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$18.0M N/A -$17.5M
2021 $2.0M -$71.8M $2.0M -$71.6M
2022 $4.9M -$58.4M $4.9M -$57.2M
2023 $33.5M -$27.7M $33.5M -$25.4M
2024 $251,000 -$58.5M $251,000 -$56.1M
2025 N/A -$83.9M -$2.6M -$81.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 N/A -$21.5M
Dec 2025 N/A -$20.8M
Mar 2026 N/A -$23.5M
Jun 2026 N/A -$25.0M

Ownership & Float

Insider Ownership15.1%
Institutional Ownership84.2%
Short Float9.4%
% of All Funds Holding0.84%
Number of Funds Holding74

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$9.55Near-term / short-term trend
Weekly40-Week SMA$8.05Medium-term trend
Weekly80-Week SMA$5.49Cyclical trend (business cycle)
Weekly200-Week SMA$0.00Secular trend (multi-year)
Monthly10-Month SMA$7.95Near-term monthly trend
Monthly20-Month SMA$5.48Medium-term monthly trend
Monthly40-Month SMA$0.00Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.90 support 7.73x 11 months ago
$1.60 support 1.44x 14 months ago

Historical Earnings Reactions (9 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.43% 0.39% 55.56% 7.25% -3.89%
1 Day -2.42% -2.68% 33.33% 17.27% -14.82%
1 Week -9.72% -6.88% 11.11% 6.19% -23.27%
2 Weeks -14.75% -10.20% 0.00% -3.48% -50.90%
1 Month -3.19% -6.62% 37.50% 39.12% -36.83%

Next earnings: November 11, 2026 (31 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.44% 43.0% 107
Tuesday -0.71% 46.1% 115
Wednesday 0.79% 51.3% 113
Thursday -0.38% 38.5% 109
Friday 1.25% 52.7% 110

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 84.2%

Insider Transactions — Smart Summary

Total insider ownership: 15.1%

12-Month Insider Activity Summary

Total Filings30
Net Value-$2.7M
Net Shares Change9,745,673
% of Float50.1%
C-Suite Filings20
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
GC Corp. +$16.5M 1 2 buy
RA CAPITAL MANAGEMENT, L.P. +$4.9M 5 5 buy
Aslan Fred Chief Executive Officer -$421,827.891 1 1 sell
Horan Christopher Chief Tech Operations Officer -$70,696.648 1 1 sell
Bush Jennifer COO, CLO, Compliance Officer -$57,227.364 1 1 sell
Banerjee Subhashis Chief Medical Officer -$7,514.083 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-05-13 – 2026-05-19 6 6 +$74.5M 5 C-suite
2026-09-04 – 2026-09-09 5 4 -$1.2M 5 C-suite
2026-10-06 – 2026-10-07 5 4 -$726,145.621 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-07-23 RA CAPITAL MANAGEMENT, L.P. +$2.6M Transaction at $9.76, now -28.9%
2026-07-20 RA CAPITAL MANAGEMENT, L.P. +$1.4M Transaction at $8.93, now -22.3%
2026-07-28 RA CAPITAL MANAGEMENT, L.P. +$412,776.81 Transaction at $9.99, now -30.5%
2026-05-28 GC Corp. +$16.5M Transaction at $11.52, now -39.8%
2026-07-31 RA CAPITAL MANAGEMENT, L.P. +$455,725.706 Transaction at $9.96, now -30.3%
2026-07-23 RA CAPITAL MANAGEMENT, L.P. +$58,306.68 Transaction at $8.94, now -22.4%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Artiva Biotherapeutics, Inc. Common Stock (ARTV) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ARTV on Trend Edge →